Liver X Receptors (LXRs) in cancer-an Eagle's view on molecular insights and therapeutic opportunities
PS Ramalingam, S Elangovan, JR Mekala… - Frontiers in Cell and …, 2024 - frontiersin.org
Cancer has become a serious health burden that results in high incidence and mortality
rates every year, mainly due to various molecular alterations inside the cell. Liver X …
rates every year, mainly due to various molecular alterations inside the cell. Liver X …
Reverse vaccinology and immunoinformatics approaches to design multi-epitope based vaccine against oncogenic KRAS
PS Ramalingam, S Arumugam - Medical Oncology, 2023 - Springer
Mutant KRAS-induced tumorigenesis is highly involved in the progression of pancreatic,
lung, and breast cancer. Comparatively, KRAS G12D and KRAS G12C are the most frequent …
lung, and breast cancer. Comparatively, KRAS G12D and KRAS G12C are the most frequent …
Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pancreatic ductal adenocarcinoma using …
Mutant KRAS promotes the proliferation, metastasis, and aggressiveness of various cancers
including pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) …
including pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) …
Exploring effective biomarkers and potential immune related gene in small cell lung cancer
Y Yunchu, A Miyanaga, K Matsuda, K Kamio… - Scientific Reports, 2024 - nature.com
Small cell lung cancer (SCLC) is well known as a highly malignant neuroendocrine tumor.
Immunotherapy combined with chemotherapy has become a standard treatment for …
Immunotherapy combined with chemotherapy has become a standard treatment for …
Computational design and validation of effective siRNAs to silence oncogenic KRAS
PS Ramalingam, S Arumugam - 3 Biotech, 2023 - Springer
Oncogenic KRAS mutations drive cancer progression in lung, colon, breast, and pancreatic
ductal adenocarcinomas. Apart from the current strategies, such as KRAS upstream …
ductal adenocarcinomas. Apart from the current strategies, such as KRAS upstream …
ML‐Based Screening of miRNA Inhibitors and Intervention of lncRNA/miRNA/mRNA Axis in Oncogenic KRAS‐Associated Colorectal Cancer
PS Ramalingam, DBTG Raj… - Advances in Public …, 2024 - Wiley Online Library
Mutant KRAS promotes proliferation and tumorigenesis in several cancers such as
colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and non–small cell …
colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and non–small cell …
System Biology Approach of Protease Cathepsin K in Glioblastoma Multiforme
PS Ramalingam, S Arumugam… - … of Proteases in …, 2024 - taylorfrancis.com
Glioblastoma (GBM) is a grade IV aggressive brain cancer with poor prognosis and survival
rates in patients. GBM recurrence is very common even after surgery and chemotherapy due …
rates in patients. GBM recurrence is very common even after surgery and chemotherapy due …